4th Quarter - Report

FAEGRE DRINKER BIDDLE & REATH LLP for TEVA PHARMACEUTICALS USA, INC.

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.

LobbyistCovered position, as disclosed
BRYAN MICHAEL ALLEN Staff Assistant, Legislative Correspondent, Legislative Aide, Sen. Susan Collins (R-ME)
MEGAN SUSSMAN HERBER Press Secretary and Legislative Assistant, Rep. Christopher H. Smith (R-NJ)
ELLIOT VICE Staff Assistant, Legislative Correspondent & Scheduler, Sen. Evan Bayh (D-IN) 2009-2010

Contacted: HOUSE OF REPRESENTATIVES

Bills named: H.R. 501 (118th), H.R. 1613 (118th), S. 150 (118th), S. 127 (118th), S. 113 (118th), H.R. 5378 (118th), S. 142 (118th)

Copyright/Patent/Trademark CPT

Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.

LobbyistCovered position, as disclosed
BRYAN MICHAEL ALLEN Staff Assistant, Legislative Correspondent, Legislative Aide, Sen. Susan Collins (R-ME)
MEGAN SUSSMAN HERBER Press Secretary and Legislative Assistant, Rep. Christopher H. Smith (R-NJ)
ELLIOT VICE Staff Assistant, Legislative Correspondent & Scheduler, Sen. Evan Bayh (D-IN) 2009-2010

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 142 (118th), S. 127 (118th), S. 150 (118th), H.R. 5378 (118th), H.R. 1613 (118th), S. 113 (118th), H.R. 501 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.